Introduction {#s1}
============

Sensory input may be an important determinant between normal and pathological cognitive aging. Over the past few years, the relationship between hearing loss and cognitive impairment has been studied extensively in the aging population. Large prospective studies have found an independent relationship between hearing loss on the one hand and age-related cognitive decline and incident dementia on the other hand (Lin et al., [@B46], [@B47]; Gallacher et al., [@B25]; Gurgel et al., [@B35]; Fulton et al., [@B23]; Castiglione et al., [@B12]; Wuyts et al., [@B80]). The mechanistic basis of this correlation remains unclear: hearing loss may accelerate cognitive decline in older adults and therefore acts as a risk factor of cognitive decline. Alternatively, hearing loss could be an early symptom of cognitive decline and could be an effect rather than a cause of cognitive impairment. A common cause that induces both pathologies may be a third underlying mechanism of the association (Martini et al., [@B51]; Peracino, [@B61]).

Cognitive deficits were also observed in animal and human studies on bilateral vestibular loss (BVL) (Smith et al., [@B69]). In individuals with BVL, increased vigilance is necessary to avoid falling, which makes multitasking difficult: e.g., patients need to stop walking in order to talk (Lundin-Olsson et al., [@B49]; Bessot et al., [@B4]). Furthermore, a reduction of gray matter volume was observed in BVL patients in the bilateral hippocampal region CA3 (Göttlich et al., [@B30]). Atrophy of the hippocampus in BVL patients resulted in emotional, navigational, spatial memory, and spatial anxiety deficits (Brandt et al., [@B10]; Fanselow and Dong, [@B21]; Kremmyda et al., [@B41]).

Hereditary hearing loss can be classified as syndromic hearing loss and non-syndromic hearing loss. DFNA9 is a cause of autosomal dominant non-syndromic late-onset sensorineural hearing loss (SNHL) associated with progressive BVL (Chen et al., [@B13]). It is caused by mutations in the COCH (coagulation factor C homology) gene, found on the long arm of chromosome 14 (14q12-q13). This gene encodes for the cochlin protein, which is highly expressed in the inner ear and found in lower levels in the spleen and very low levels in the eye, cerebellum and brain stem, kidney and liver (Bischoff et al., [@B5]; Li et al., [@B44]; Cho et al., [@B14]).

The function of cochlin is not fully understood though it is known to assist in structural support, sound processing, and maintenance of balance within the inner ear (Gallant et al., [@B26]). Animal models suggests an immune-mediating effect by regulating cytokine production, recruitment of immune effector cells, and bacterial clearance (Py et al., [@B63]). DFNA9 overexpression is also associated with raised intraocular pressure within patients and mice (Bischoff et al., [@B6]; Goel et al., [@B29]; Verbecque et al., [@B77]).

Although the pathophysiology behind the progressive bilateral cochleovestibular loss is not entirely understood, mutated cochlin deposits in the inner ear are considered pathognomonic (Robertson et al., [@B64]). Recent work has established the individual impact of hearing impairment as well as BVL on quality of life (QoL) and cognitive function (Smith et al., [@B69]; Vermeire et al., [@B79]; Guinand et al., [@B33]; Besnard et al., [@B3]; Popp et al., [@B62]).

Our objective was to perform a systematic review on DFNA9, specifically focusing on its phenotype, genotype, pathophysiology, histologic findings, imaging findings, QoL on the one hand and its effect on cognitive function on the other hand.

Materials and methods {#s2}
=====================

The strategy used and the reporting hereafter is based on the Meta-analysis of Observational Studies in Epidemiology statement (Stroup et al., [@B71]), and follows Cochrane guidelines (Green, [@B32]).

We focused on several bibliographical databases to identify relevant reports in English: Medline, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, ISI Web of Knowledge, and Web of Science. The search was performed on 1 July 2016, and also included articles published ahead of print. The global search term was adapted to all databases (Green, [@B32]; Scholten et al., [@B68]). We searched for etiology, pathophysiology, QoL, MRI, CT, and cognitive function as outcome (O) of the studies. We included studies in English. Single case reports and systematic reviews were excluded.

The following search terms were combined for the PubMed / Medline search: (((((bilateral vestibulopathy) OR vestibular areflexia) OR DFNA9) OR Bilateral semicircular canal stenosis) OR semicircular canal fibrosis) AND ((((((Causality\[Mesh\]) OR Etiology\[Subheading\]) OR Pathophysiology\[Subheading\]) OR QoL) OR CT) OR MRI OR Cognitive function) For Web of Science, the following search terms were used: \[TS = (bilateral vestibulopathy) OR TS = (vestibular areflexia) OR TS = (DFNA9) OR TS = (Bilateral semicircular canal stenosis) OR TS = (semicircular canal fibrosis)\] AND \[TS = (Causality) OR TS = (Etiology) OR TS = (Pathophysiology) OR TS = (QoL) OR TS = (CT) OR TS = (MRI) OR TS = Cognitive function\].

All studies were screened for eligibility in two screening phases based on the inclusion and exclusion criteria. In the first phase, all studies were screened on title and abstract by two reviewers (JDB, SM). If there was no abstract present but the title was applicable, the study was included to the second phase. In the second phase, the studies were screened in full-text using the same inclusion and exclusion criteria. The flow of included articles can be found in Figure [1](#F1){ref-type="fig"}.

![Systematic study inclusion. Studies were excluded if they conformed to the following criteria: Population: unilateral vestibulopathy, absence of DFNA9, pathology not concerning bilateral vestibulopathy or not cause by DFNA9 mutation. Intervention, not strictly observational; Outcome, When the goal of the study was not to acquire data involving the etiology or pathophysiology; Design, Reviews and single case studies; Language, Not English or Dutch. Double, If found in more than one database that article was only used once.](fnins-11-00735-g0001){#F1}

The articles written by Dodson et al. ([@B20]) and (Choi et al. ([@B15]) were added based on references within other relevant articles. To get a better understanding of the function of cochlin within the eye we also included Goel et al. ([@B29]).

Results {#s3}
=======

Phenotype
---------

DFNA9 is characterized by progressive bilateral SNHL. The age of onset varies depending on the mutation although the average age of onset lies around the 3rd−5th decade (Chen et al., [@B13]). SNHL typically starts in the higher frequencies at the age of onset with an evolution toward deafness (Bom et al., [@B8]; Gao et al., [@B27]).

Dizziness is another important clinical aspect in most cases. Patients may initially complain of episodic vertigo spells and evolve toward BVL, which causes oscillopsia and imbalance (especially in the dark), difficulty while cycling etc. The vestibular symptoms generally present themselves a few years after the SNHL onset although there are some mutations where the vestibular symptoms present themselves simultaneously or even prior to SNHL onset (G88E, P51S, G87V, G87W; Bom et al., [@B7],[@B9]; Khetarpal, [@B40]; Bischoff et al., [@B5]; Kemperman et al., [@B39]; Collin et al., [@B17]; Chen et al., [@B13]). One exception was found, i.e., the P98H mutation, which presented with unilateral congenital hearing loss in a single case. (Dodson et al., [@B20]) The presentation of Ménière-like symptoms (tinnitus, vertigo spells, and hearing loss) is not uncommon. However, Ménière\'s disease typically presents with a more fluctuating pattern of hearing and vestibular symptoms, and a low-frequency SNHL. (Fransen et al., [@B22]; Wuyts et al., [@B80]) BVL symptoms may lead to reduced vitality, fear of falling and reduced general health, further described in the "QoL" paragraph. One study has also documented the absence of cervical vestibular-evoked myogenic potentials (cVEMPs), indicating saccular otolithic deficits (Robertson et al., [@B66]).

Genotype
--------

The COCH gene is located on chromosome 14q12-13 which encodes for cochlin (Manolis et al., [@B50]). We identified 24 different mutations in the COCH gene, autosomal dominantly inherited and heterozygous (Table [1](#T1){ref-type="table"}). COCH encodes for a 550-amino-acid protein called cochlin. The COCH gene contains the following domains: an N-terminal signal peptide (SP), a late gestation lung protein Lgl1 (LCCL) domain, two vWFA domains (von Willebrand factor A-like) and two short intervening domains (ivd) (Robertson et al., [@B67]; Gallant et al., [@B26]; Bae et al., [@B2]). The vestibular symptoms are more correlated with mutations within the LCCL domain than to mutations within the vWFA domains. Individuals with mutations within the vWFA domain usual have an earlier onset of hearing loss than those with mutations in the LCCL domain (Bae et al., [@B2]).

###### 

Known COCH mutations and clinical features.

  **Effected protein**   **Domain**    **Progressive hearing loss**   **Decade of onset**   **Vestibular involvement**   **Accompanied by tinnitus**   **Ethnicity**   **References**
  ---------------------- ------------- ------------------------------ --------------------- ---------------------------- ----------------------------- --------------- ------------------------------------------------
  p.A119T                LCCL          Yes                            4th                   Present in all               --                            Japanese        Pauw et al., [@B59]
  p.A487P                vWFA2         Yes                            2^nd^                 Present in some              --                            Italian         Bae et al., [@B2]
  p.C162Y                Intervening   Yes                            2nd                   Not present                  --                            Chinese         Gao et al., [@B27]
  p.C542F                vWFA2         Yes                            2nd−5th               Present in some              --                            USA             Street et al., [@B70]; Yuan et al., [@B82]
  p.C542R                vWFA2         Yes                            2nd                   Present in one               --                            Japanese        Tsukada et al., [@B73]
  p.C542Y                vWFA2         Yes                            2nd−5th               Not present                  Frequent (82%)                Chinese         Yuan et al., [@B82]
  p.F121S                LCCL          Yes                            2nd−3rd               Present in all               Common                        USA             Hildebrand et al., [@B36]
  p.F527C                vWFA2         Yes                            N.A.                  Not present                  --                            Korean          Cho et al., [@B14]
  p.G38D                 LCCL          Yes                            N.A.                  N.A.                         N.A.                          Korean          Choi et al., [@B15]
  p.G87V                 LCCL          Yes                            4th                   Present in all               Sometimes                     Chinese         Chen et al., [@B13]
  p.G87W                 LCCL          Yes                            5th                   Present in all               --                            Dutch           Collin et al., [@B17]; Pauw et al., [@B58],b
  p.G88E                 LCCL          Yes                            4th−7th               Present in some              --                            Dutch, USA      Kemperman et al., [@B39]
  p.I109N                LCCL          Yes                            2nd−3rd               Present in all               --                            Australian      Kamarinos et al., [@B38]
  p.I109T                LCCL          Yes                            4th−6th               Present in all               --                            Dutch           Pauw et al., [@B60]
  p.I372T                vWFA2         Yes                            4th−5th               Not present                  --                            Japanese        Tsukada et al., [@B73]
  p.Ile399_Ala404del     vWFA2         Yes                            3rd                   Not present                  Common                        USA             Gallant et al., [@B26]
  p.L114P                LCCL          Yes                            N.A.                  N.A.                         N.A.                          Korean          Choi et al., [@B15]; Burgess et al., [@B11]
  p.M512T                vWFA2         Yes                            5th                   Not present                  Sometimes                     Chinese         Yuan et al., [@B82]
  p.P51S                 LCCL          Yes                            2rd−5th               Present in all               Common                        Dutch, USA      Lemaire et al., [@B42]; Bischoff et al., [@B5]
  p.P89H                 LCCL          Yes                            Congenital            N.A.                         --                            USA             Dodson et al., [@B20]
  p.V104del              LCCL          Yes                            4th                   Present in all               --                            Hungarian       Nagy et al., [@B55]
  p.V123E                LCCL          Yes                            4th−6th               Not present                  --                            N.A.            Jung et al., [@B37]
  p.V66G                 LCCL          Yes                            2nd−3rd               Present in some              --                            USA             Grabski et al., [@B31]
  p.W117R                LCCL          Yes                            3rd                   Present in some              --                            Korean, USA     Nagy et al., [@B56]; Tsukada et al., [@B73]

*Decade of onset of either hearing loss, vestibular symptoms or both. In most mutations hearing loss precedes vestibular symptoms by a few years; N.A., no data available; Dutch, The Netherlands and Belgium*.

Several COCH mutations originate from specific locations such as North America, Japan, Australia, Korea, China, and Belgium/the Netherlands. For the Pro51Ser mutation a Dutch founder was discovered (de Kok et al., [@B18]; Verhagen et al., [@B78]).

Pathophysiology
---------------

The DFNA9 mutations lead to the production of mutated cochlin. Since the exact physiological role of cochlin is yet to be discovered, the pathophysiological relevance of mutated cochlin is still unknown.

Different pathophysiological mechanisms have been described for different mutations, although they lead to similar phenotypes (Liepinsh et al., [@B45]; Robertson et al., [@B65]; Yao et al., [@B81]; Bae et al., [@B2]; Jung et al., [@B37]). For the mutations p.V104del, p.I109T, and p.F121S located on the Limulus factor C, cochlin, and LCCL domain and p.C162Y, p.A487P located on the vWFA domains Bae et al. found that they were not secreted into the media (Yao et al., [@B81]). A failure in transport from the endoplasmatic reticulum to the Golgi complex leading to accumulation within the cell was documented for the latter mutations. Dimeric aggregates and multimeric aggregates are the product of protein misfolding (Grabski et al., [@B31]; Robertson et al., [@B65]; Street et al., [@B70]; Yao et al., [@B81]; Cho et al., [@B14]). LCCL domain mutations were found to form intracellular dimeric aggregates while mutations in vWFA domains lead to the formation of multimeric aggregates. High-molecular-weight aggregates are linked to early onset of hearing loss in DFNA9 patients whereas dimeric aggregates are associated with a later age of onset (Cho et al., [@B14]; Bae et al., [@B2]). For the vWFA domain mutations p.F527C and p.C542Y intracellular accumulation of multimeric cochlin was found, however monomeric secretions of mutant cochlin reach similar levels as in wild-type. COCH mutations in the LCCL domain are dominated by vestibular symptoms, while mutations in the vWFA predominantly lead to hearing loss. (Nagy et al., [@B55]; Bae et al., [@B2]).

Another pathophysiological mechanism involving decreased secretion is reduced cleavage of intracellular cochlin by aggrecanase, described for p.P51S, p.V66G, p.G88E, p.I109T, p.W117R, p.V123E, and p.C162Y. Wild type cochlin is cleaved by aggrecanase after which the LCCL-domain is secreted into the extracellular compartment. The c-terminal domain remains intracellular (Py et al., [@B63]; Jung et al., [@B37]). Because of the misfolding, post-translational cleavage of mutated cochlin is impaired. This leads to a reduction in secretion of the LCCL domain to the extracellular compartment. The absence of cleaved LCCL within the inner ear would lead to a reduced inflammatory reaction because of the innate immune function of LCCL, which eventually leads to an accumulation of endotoxins within the inner ear and the characteristic late-onset bilateral cochleovestibular deficiency (Bae et al., [@B2]).

Other hypotheses involving the normal secretion of mutated cochlin speak of impaired integration in the extracellular matrix (ECM) leading to structural changes in the matrix of the cochleovestibular system (Grabski et al., [@B31]; Robertson et al., [@B64]) or extracellular dimerization and multimerization, this is yet to be further elucidated (Yao et al., [@B81]; Jung et al., [@B37]).

Histology
---------

McCall et al. ([@B52]) found that temporal bones of DFNA9 patients had abnormal mixed eosinophilic deposits within the cochlea and vestibular labyrinth, the tympanic membrane, incudomallear, and incudostapedial joint. In the middle ear, deposits in the tympanic membrane cause a thickening of the middle layer. The deposits resembled the morphology of cartilage. Other mobile areas within the middle ear such as the stapediovestibular joint, tensor tympani tendon, anterior malleal ligament, and incudal ligament did not reliably demonstrate similar deposits. Important to note is that these histological findings are different to those of the inner ear.

Within the inner ear, the presence of eosinophilic cochlin deposits is considered pathognomonic for DFNA9. These deposits are acellular and homogenous as found by Robertson et al. (Goel et al., [@B29]) Electron microscopy of the inner ear section in DFNA9 patients shows a highly branched, densely packed and haphazardly branched microfibrillar substance. Only one type of microfibrils is detected which is 20 nm or less in size. These findings are in contrast with the extracellular matrix of healthy individuals where multiple types of microfibrils are periodically banded with a moderate amount of space between the bundles (Bom et al., [@B8]).

Imaging
-------

Limited evidence is available on sclerotic lesions and/or narrowing of one of the semicircular canals in DFNA9. These findings have been observed on T2-weighted MRI images as a phenotypic radiological feature of DFNA9 by de Varebeke et al. ([@B19]) who also found that the fibrotic process within the inner ear is only later followed by ossification. However, Van Rompaey et al. ([@B76]) demonstrated afterwards that these findings are also present in patients with simultaneous cochleovestibular deficiency compared to patients who only have bilateral deafness. Since there is a correlation between MRI abnormalities and lateral semicircular canal function loss they proposed T2-weighted MRI as possible biomarker for BVL in general.

Quality of life
---------------

BVL often leads to a decreased QoL, as reported by Guinand et al. ([@B33]), who have studied QoL in a general BVL population, including four DFNA9 patients. Several health-related QoL instruments were used to study the impact of BVL overall, including the Short-Form Health Survey (SF-36), Dizziness Handicap Inventory (DHI), and the Short Falls Efficacy Scale-International (Short FES-I) (Guinand et al., [@B33]). Physical functioning, general health, vitality, and social functioning were significantly impaired (compared to the general Dutch population), meaning that both physical, and mental QoL is significantly decreased in these patients (Guinand et al., [@B33]). Thirty-three BVL patients (85%) had a score of 30 or higher (moderate self-perceived handicap), of which 17 (44%) had a score of 60 or higher (severe self-perceived handicap). The Short FES-I is a questionnaire used to assess the fear of falling. Only seven patients reported to have no fear of falling, whereas 29 patients (74%) had a slight to moderate fear. Three patients with BVL (8%) had a severe fear of falling. To evaluate oscillopsia, a specific questionnaire was reported by Guinand et al. ([@B33]) Due to its chronic nature patients tend to report less inconvenience by oscillopsia over time due to habituation, though the questionnaire still revealed a significant impact on daily life.

Vermeire et al. (Vermeire et al., [@B79]; Castiglione et al., [@B12]) describe a significant improvement in QoL and speech-recognition in DFNA9 patients after cochlear implantation. They used the Hearing Handicap Inventory for Adults, the Glasgow Benefit Inventory, and the Scale for the Prediction of Hearing Disability in SNHL (Vermeire et al., [@B79]).

Cognitive impairment
--------------------

Numerous studies have already described the correlation between hearing impairment and cognitive decline. (Fulton et al., [@B23]; Miller et al., [@B54]; Castiglione et al., [@B12]; Claes et al., [@B16]) In DFNA9 patients, the impact on QoL of SNHL and cochlear implantation was studied, without focusing on cognitive impairment (Vermeire et al., [@B79]; Castiglione et al., [@B12]). No data were available on the evaluation of cognition in DFNA9 patients or BVL in general at the time of the literature search. Afterwards, Popp et al. reported on data suggesting cognitive impairment in BVL patients (Popp et al., [@B62]).

Discussion {#s4}
==========

DFNA9 is an autosomal dominant non-syndromic disorder characterized by late-onset SNHL associated with progressive BVL (Chen et al., [@B13]). This systematic review is characterized by a transparent search strategy and study selection.

The pathophysiology is not yet fully elucidated, although all documented mutations share roughly the same phenotype, including late-onset SNHL and BVH. Some exceptions have been documented, p.P89H is associated with congenital SNHL, while p.C162Y, p.C542Y, p.F527C, p.I372T, p.Ile399_Ala404del, and p.M512T are not associated with BVL.

QoL has not been studied extensively in DFNA9, although scarce work is available on the positive QoL impact of cochlear implantation to rehabilitate hearing (Vermeire et al., [@B79]; Castiglione et al., [@B12]). Currently, no treatments are available clinically to restore vestibular function. The treatment consists mainly of specific exercises and informing the patient. Practical information such as fall risk precautions is discussed (Furman et al., [@B24]). To restore vestibular function, several centers have studied the possibility of a vestibular implant (Lewis, [@B43]). In analogy to the cochlear implant, the vestibular implant sends electronic signals to the vestibular system. In doing so, it imitates normal vestibular function and provides the central nervous system with motion information (van de Berg et al., [@B75], [@B74]; Merfeld and Lewis, [@B53]; Thompson et al., [@B72]; Guinand et al., [@B34]). Even in an etiologically heterogeneous patient population (including DFNA9 patients), a vestibular implant could be an effective way to activate the vestibular system and have a significant impact on QoL of BVL patients (Guinand et al., [@B34]).

Several studies have been conducted on the impact of hearing loss on cognition (Lin et al., [@B47]; Fulton et al., [@B23]; Miller et al., [@B54]; Castiglione et al., [@B12]; Claes et al., [@B16]). Lin et al. performed a large prospective study with 1,984 older adults of which there were 1,162 hearing impaired. They evaluated the cognitive state during multiple years, and concluded that hearing loss is an independent factor that causes an acceleration of cognitive decline. The progression of the cognitive decline is linear to the progression of the hearing deterioration. The mechanism of this link between hearing and cognitive decline is still to be further examined (Miller et al., [@B54]).

Few studies have been conducted on the impact of BVL on cognition. Some animal models and patient studies documented hippocampal deterioration following vestibular dysfunction leading to impaired spatial memory. Also, over several patient studies deficits in memory, spatial memory, perception, attention, and ability to analyze information were found. Moreover, in some cases a correlation was found between the severity of the vestibular symptoms and cognitive impairment (Smith et al., [@B69]). However, in 2003 an epidemiological study, involving 200 patients, conducted by Gizzi et al. found no significant correlation between the diagnosis of vestibular dysfunction and the presence of cognitive complaints (Gizzi et al., [@B28]). The correlation between BVL and cognitive tasks involving spatial tasks has always been the strongest. Popp et al. recently found a significant impairment of visuospatial abilities, processing speed, short-term memory. and executive functions in BVL patients. They compared unilateral vestibular loss (UVL) with BVL and controls and found a significant difference in cognitive deterioration between patients with BVL and UVL. For patients with UVL they documented significant impairment in visuospatial skills and reduced processing speed, the latter only in some cases.

Since there is a correlation between BVL and cognitive deterioration specifically in spatial domains, even for non-spatial skills a strong similar deterioration can be expected in DFNA9 patients (Popp et al., [@B62]). However, DFNA9 patients also suffer from hearing loss, which may also affect immediate memory, language, attention, and delayed memory. We would therefore anticipate a combined detrimental effect on cognition. For this reason, we conducted a systematic review on the available literature. However, we were unable to find studies evaluating cognition in patients affected by BVL and SNHL such as in DFNA9.

There are many instruments to evaluate the cognitive function of a patient. The most frequently used are the Montreal Cognitive Assessment (MoCa), Mini-Mental State Exam (MMSE), Addenbrooke\'s Cognitive Examination revised version (ACE-R), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Neurobehavioral Cognitive Screening Examination (NCSE), etc. When comparing MMSE, MoCa, and RBANS a strong correlation is found between the score of RBANS and MOCA, while only RBANS has a strong correlation with total brain volume (Paul et al., [@B57]; Lin et al., [@B48]). While the MOCA can screen for mild cognitive impairment and the MMSE is used more frequently in Alzheimer\'s disease, the RBANS has more potential as a tool in case repeated measures are required, e.g. prospective follow-up studies. The RBANS also has the benefit of generating one outcome measure (instead of focussing on one aspect such as d2, Boston Name, etc.) and its easy application in an ENT clinic. Two other tools that also offer this benefit are Alzheimer\'s Disease Assessment Scale Cognitive (ADAS-Cog) and Mattis Dementia Rating Scale (MDRS), however ADAS-Cog does not test executive functions, which was found to be impaired in patients with vestibular dysfunction. (Popp et al., [@B62]) Both MDRS and RBANS require verbal communication with the patient, which makes the results questionable when used in studies including patients with hearing impairment (Appels and Scherder, [@B1]). However, an adjusted version of the RBANS, the RBANS-H, has been drafted especially for patients with impaired hearing, overcoming the bias caused by hearing impairment within these cognitive assessment tools (Claes et al., [@B16]).

Conclusion {#s5}
==========

Cognitive impairment has been demonstrated in several studies in patients with hearing loss and in one study on patients with bilateral vestibular failure. However, no studies have been reported in DFNA9, where patients are affected by combined otovestibular failure. Further research is warranted to correlate otovestibular status with cognition.
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